XLRN Stock Chart

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. The Company's research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s capacity for cellular growth and repair. The Company’s lead product candidate, luspatercept, is being evaluated in two Phase 3 studies in a global partnership with Celgene to treat chronic, sometimes debilitating anemias in myelodysplastic syndromes (MDS) and beta-thalassemia. Acceleron is also advancing clinical programs in neuromuscular disorders and cancer, and preclinical research in fibrotic and other diseases.